Detalhe da pesquisa
1.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer
; 130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
2.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol
; 204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
3.
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Blood
; 139(9): 1289-1301, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521108
4.
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Am J Hematol
; 99(2): 245-253, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100199
5.
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
Am J Hematol
; 99(4): 562-569, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38314663
6.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Am J Hematol
; 99(5): 836-843, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400519
7.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021929
8.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol
; 202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376789
9.
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Mod Pathol
; 36(6): 100166, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990279
10.
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
BMC Cancer
; 23(1): 1258, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38124057
11.
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Am J Hematol
; 98(1): 140-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567778
12.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol
; 98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327
13.
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Haematologica
; 107(4): 899-908, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951890
14.
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Hematol Oncol
; 40(1): 48-56, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763367
15.
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Cancer
; 127(22): 4233-4239, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374445
16.
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
BMC Cancer
; 21(1): 730, 2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172037
17.
POEMS syndrome: A multisystem clonal disorder.
Eur J Haematol
; 106(1): 14-18, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32889731
18.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
Acta Haematol
; 144(1): 74-81, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604096
19.
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.
Biol Blood Marrow Transplant
; 26(8): 1439-1445, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438043
20.
Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 26(1): 197-203, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31518645